The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05384119
Recruitment Status : Completed
First Posted : May 20, 2022
Last Update Posted : May 30, 2024
Sponsor:
Information provided by (Responsible Party):
Tvardi Therapeutics, Incorporated

Brief Summary:

The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal receptor 2-negative (HER2)- palbociclib-resistant breast cancer, and to determine the recommended Phase 2 dose (RP2D) for TTI-101 when added to palbociclib and AI or fulvestrant.

The primary objective of Phase 2 will be to evaluate anti-tumor activity in participants who receive TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: TTI-101 Drug: Palbociclib Drug: Aromatase inhibitor (AI) Drug: fulvestrant Drug: ribociclib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Actual Study Start Date : January 9, 2023
Actual Primary Completion Date : April 25, 2024
Actual Study Completion Date : April 25, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1b: Dose Escalation
Participants will receive up to 3 dose levels of TTI-101 added to palbociclib and AI or fulvestrant to determine the RP2D.
Drug: TTI-101
Oral tablet

Drug: Palbociclib
Oral capsule
Other Name: Ibrance ®

Drug: Aromatase inhibitor (AI)
Oral tablet

Drug: fulvestrant
Oral tablet

Experimental: Phase 2: Dose Expansion
Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
Drug: TTI-101
Oral tablet

Drug: Palbociclib
Oral capsule
Other Name: Ibrance ®

Drug: Aromatase inhibitor (AI)
Oral tablet

Drug: fulvestrant
Oral tablet

Drug: ribociclib
Oral tablet




Primary Outcome Measures :
  1. Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT) [ Time Frame: Day 1 to Day 28 ]
  2. Phase 1b: Number of Participants Who Experience an Adverse Event (AE) [ Time Frame: Up to approximately 18 months ]
    An AE is any untoward medical occurrence in a participant or clinical study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Any clinically significant changes between baseline and postbaseline laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations will be recorded as AEs.

  3. Phase 1b: Number of Participants Who Experience a Serious Adverse Event (SAE) [ Time Frame: Up to approximately 18 months ]
  4. Phase 2: Landmark Progression Free Sulrvival at 6 Months (PFS6) [ Time Frame: Day 1 pre-dose and 6 months post-dose ]

Secondary Outcome Measures :
  1. Phase 1b: PFS6 [ Time Frame: Day 1 pre-dose and 6 months post-dose ]
  2. Phase 1b and Phase 2: Clinical Benefit Rate (CBR) [ Time Frame: Up to approximately 18 months ]
    Defined as complete response (CR) + partial response (PR) + stable disease (SD) for at least 6 months.

  3. Phase 1b and Phase 2: Overall Response Rate (ORR) [ Time Frame: Up to approximately 18 months ]
    Defined as complete response (CR) + partial response (PR) measured in all participants using RECIST Version 1.1.

  4. Phase 1b and Phase 2: Overall Response Rate (ORR) [ Time Frame: Up to approximately 18 months ]
    Defined as complete response (CR) + partial response (PR) measured using RECIST Version 1.1 in participants who have a follow-up on-study tumor assessment at least 42 days following Cycle 1 Day 1 (cycle is 28 days) and who receive at least 80% of scheduled dosing with TTI-101.

  5. Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of TTI-101 [ Time Frame: Cycle 2 Day 1 (cycle is 28 days) ]
  6. Phase 1b and Phase 2: Time of Maximum Observed Plasma Concentration (Tmax) of TTI-101 [ Time Frame: Cycle 2 Day 1 (cycle is 28 days) ]
  7. Phase 1b and Phase 2: Area Under the Plasma Concentration-time Curve from Time 0 to Time t (AUC[0-t]) of TTI-101 [ Time Frame: Cycle 2 Day 1 (cycle is 28 days) ]
  8. Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 1 (pY-STAT1) Positive Cells in Tumor Biopsy Samples [ Time Frame: Baseline to Cycle 3 Day 1 (cycle is 28 days) ]
  9. Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 3 (pY-STAT3) Positive Cells in Tumor Biopsy Samples [ Time Frame: Baseline to Cycle 3 Day 1 (cycle is 28 days) ]
  10. Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples [ Time Frame: Baseline to Cycle 3 Day 1 (cycle is 28 days) ]
  11. Phase 1b and Phase 2: Duration of Response (DoR) to Treatment [ Time Frame: Up to approximately 18 months ]
  12. Phase 1b and Phase 2: Time to Tumor Progression (TTP) [ Time Frame: Up to approximately 18 months ]
  13. Phase 1b and Phase 2: Best Overall Response (BOR) [ Time Frame: Up to approximately 18 months ]
  14. Phase 2: Progression-free Survival (PFS) [ Time Frame: Up to approximately 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must meet all the following criteria to be eligible:

  1. Age ≥18 years at the time of informed consent.
  2. Metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
  3. For Phase 1b,currently receiving palbociclib and AI or fulvestrant; for Phase 2, currently receiving palbociclib or ribociclib and AI or fulvistrant therapy in the metastatic setting with evidence of progressive disease. In addition:

    • Must have remained on palbociclib or ribociclib and AI or fulvestrant therapy for ≥6 months for advanced breast cancer or metastatic disease prior to evidence of progression that in the opinion of the treating physician warrants continued therapy with palbociclib or ribociclib and AI or fulvestrant.
    • Dosage of palbociclib, ribociclib, AI and fulvestrant must remain unchanged from regimen prior to study enrollment specifically palbociclib at a dose of 125, 100, or 75 mg administered orally for 21 days every 28-day cycle or ribociclib at a dose of 200, 400, or 600 mg administered orally for 21 days every 28-day cycle.
  4. All men and premenopausal women must be on medical gonadal suppression therapy with a gonadotropin analog (e.g, goserelin or leuprolide) and have estrogen levels in the postmenopausal range by institutional criteria at baseline.
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has documented confirmation of histological or cytological HR-positive, HER2-negative breast cancer per local laboratory testing.
  7. Up to 2 prior lines of systemic treatment (most recent line of therapy must be palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2) in the locally advanced or metastatic setting is allowed; the participant must have shown evidence of progressive disease on palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2 in the locally advanced or metastatic setting prior to enrollment.
  8. Willing to provide a representative fresh tumor tissue specimen prior to enrollment. The fresh tumor specimen must be obtained after evidence of progression on palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2.

    • Participants with bone only disease WITHOUT a soft tissue component, may opt out of the tumor biopsy.

  9. The presence of measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 is preferred but not required. Lesions in a previously irradiated area that have not progressed are not considered measurable.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be eligible:

  1. Has received more than 2 lines of prior systemic therapy for locally advanced/metastatic breast cancer.
  2. Had prior exposure to any signal transducer and activator of transcription 3 (STAT3) inhibitor.
  3. Had radiotherapy within 3 weeks prior to Cycle 1 Day 1 (cycle is 28 days). Participants must have recovered from radiotherapy toxicities prior to starting study treatment and recovered to Grade 1 or better from related side effects of such therapy (with the exception of alopecia).
  4. Has HER2 overexpression by local laboratory testing (immunohistochemical [IHC] 3+ or in situ hybridization positive).
  5. Has known loss of retinoblastoma tumor suppressor gene (Rb) (testing not mandatory).
  6. Has had disease progression on more than two cyclin-dependent kinase (CDK)4/6 inhibitors. Adjuvant abemaciclib is allowed but must have progressed on palbociclib or ribociclib.
  7. Concurrently using other anticancer therapy. Participants must continue palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05384119


Locations
Layout table for location information
United States, Florida
Holy Cross Health Fort Lauderdale - Holy Cross Hospital
Fort Lauderdale, Florida, United States, 33308
United States, Missouri
Washington University School of Medicine Siteman Cancer Center
Saint Louis, Missouri, United States, 63110
United States, Tennessee
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States, 75246
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States, 75390
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Tvardi Therapeutics, Incorporated
Layout table for additonal information
Responsible Party: Tvardi Therapeutics, Incorporated
ClinicalTrials.gov Identifier: NCT05384119    
Other Study ID Numbers: TVD-101-002B
First Posted: May 20, 2022    Key Record Dates
Last Update Posted: May 30, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tvardi Therapeutics, Incorporated:
Breast cancer
HR+ HER2-, palbociclib-resistant breast cancer
TTI-101
STAT3 Inhibitor
Palbociclib
Aromatase inhibitor
ribociclib
fulvestrant
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Palbociclib
Aromatase Inhibitors
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors